All In Biotech

NDA 212102 · Ucb INC

Fintepla

Fenfluramine Hydrochloride · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 25, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

26

12 Phase 3, 4 recruiting

FAERS reports

5,252

4,328 serious, 135 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION FINTEPLA can cause valvular heart disease and pulmonary arterial hypertension [see Warnings and Precautions (5.1) ]. Echocardiogram assessments are required before, during, and after treatment with FINTEPLA. The benefits versus the risks of initiating or continuing FINTEPLA must be considered, based on echocardiogram findings [see Dosage and Administration (2.1 , 2.6 ) and Warnings and Precautions (5.1) ]. Because of the risks of valvular heart disease and pulmonary arterial hypertension, FINTEPLA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FINTEPLA REMS [see Warnings and Precautions (5.2) ]. WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION See full prescribing information for complete boxed warning. FINTEPLA can cause valvular heart...

What it is approved for

From the label in effect Oct 22, 2026.

FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older. ( 1 )

Mechanism: The precise mechanism by which fenfluramine exerts its therapeutic effects in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome is unknown. Fenfluramine and the metabolite, norfenfluramine, exhibit agonist activity at serotonin 5-HT2 receptors. There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine and norfenfluramine, and valvular heart disease and pulmonary arterial hypertension.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 25, 2022 Supplement 3 · Efficacy · priority review OrphanLabelLetter
  • Jun 25, 2020 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
  • FINTEPLA · FENFLURAMINE HYDROCHLORIDE EQ 2.2MG BASE/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fenfluramine" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure2,298
  • drug ineffective795
  • tricuspid valve incompetence722
  • off label use610
  • decreased appetite593
  • somnolence502
  • weight decreased491
  • mitral valve incompetence424
  • fatigue372
  • diarrhoea334
  • generalised tonic-clonic seizure290
  • hospitalisation276

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20055
20061
20076
20082
20091
20102
20112
20122
20133
20151
20163
20173
20184
201911
202044
2021451
2022743
2023602
2024910
20251,357
20261,095

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fintepla (Fenfluramine HCl)

2024 spending

$40.9M

Beneficiaries

292

2,456 claims

Per beneficiary

$140,018

$55.08 per unit

View as table
YearSpending
2020$225,197
2021$1,760,999
2022$7,233,074
2023$17,962,601
2024$40,885,327

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 420 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.